Real-world management of chronic myeloid leukemia in South Korea: the TARGET survey
Jieun Uhm1, Kyoung Ha Kim2, Hyewon Lee3, Hawk Kim4, Slader Cassandra5, Inkyung Joo6, Chul Won Jung7
Division of Hematology Oncology, Department of Internal Medicine, 1Hanyang University Hospital, Hanyang University College of Medicine, 2Soonchunhyang University College of Medicine, Seoul, 3Division of Tumor Immunology and Center for Hematologic Malignancies, Research Institute and Hospital, National Cancer Center, Goyang, 4Division of Hematology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, 5Novartis, Ltd., 6Novartis Korea, 7Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Correspondence to: Chul Won Jung, M.D., Ph.D.
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan
University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Published online: January 28, 2021.
© The Korean Journal of Hematology. All rights reserved.

Background: The global TARGET survey examined real-world management of chronic myeloid leukemia (CML) compared with international guideline recommendations. This report focused on the responses of physicians from South Korea compared with those of physicians from the rest of the world (ROW).
Methods: The self-administered, online survey, comprising 23 questions and clinical case scenarios, was completed between April and August 2017. It was designed to gather information on practicing physicians and local practices for CML diagnosis, disease monitoring, treatment, and adverse event (AE) management.
Results: While there were similarities in the mutation analysis and treatment efficacy between Korea and the ROW, there were also differences in CML management. Initial diagnostic testing was more comprehensive in Korea than in the ROW, and there was significantly better access to standardized polymerase chain reaction testing. Assessment of BCR-ABL levels during the first 12 months of treatment was excellent in Korea, and there was greater frontline use of second-generation BCR-ABL tyrosine kinase inhibitors. Korean physicians were significantly less likely to switch therapy for hematologic AEs. Treatment-free remission was not an important goal of therapy among Korean or ROW physicians.
Conclusion: This study identified some differences in the current CML management between Korea and the ROW; CML management in Korean patients was generally in line with the current guidelines.
Keywords: chronic myeloid leukemia, management, tyrosine kinase inhibitors, real-life practice, treatment-free remission


This Article

Current Issue


Indexed/Covered by

Today : 105  /
Total : 265,549